SCHEMBL3770150

SCHEMBL3770150

CC(C)(C)OC(=O)N[C@@H](CC(Cc1ccccc1)C(N)=O)C(=O)O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACE P12821 1/20 0.60
PPARA Q07869 5/20 0.58
PPARG P37231 4/20 0.58
CTSS P25774 3/20 0.56
CTSK P43235 2/20 0.56
CTSL P07711 1/20 0.56
CTSB P07858 1/20 0.56
APP P05067 3/20 0.56
PSEN1 P49768 1/20 0.56
PSEN2 P49810 1/20 0.56
APH1B Q8WW43 1/20 0.56
NCSTN Q92542 1/20 0.56
APH1A Q96BI3 1/20 0.56
PSENEN Q9NZ42 1/20 0.56
REN P00797 2/20 0.55
NAALAD2 Q9Y3Q0 1/20 0.54
FOLH1 Q04609 1/20 0.54
ATM Q13315 1/20 0.52
PPARD Q03181 2/20 0.50
MAPK1 P28482 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20836770 0.91 NAALAD2 (0.66) ACEPPARAPPARGCTSSCTSK
SCHEMBL9439238 0.91 NAALAD2 (0.66) ACEPPARAPPARGCTSSCTSK
SCHEMBL8684458 0.91 NAALAD2 (0.66) ACEPPARAPPARGCTSSCTSK
SCHEMBL1323164 0.91 NAALAD2 (0.66) ACEPPARAPPARGCTSSCTSK
SCHEMBL4304258 0.86 ACE (0.57) ACEPPARAPPARGCTSSCTSK
SCHEMBL2173588 0.84 REN (0.67) ACEPPARAPPARGCTSSCTSK
SCHEMBL4420859 0.84 REN (0.67) ACEPPARAPPARGCTSSCTSK
SCHEMBL7618822 0.84 REN (0.67) ACEPPARAPPARGCTSSCTSK
SCHEMBL66220 0.84 ACE (0.79) ACEPPARAPPARGCTSSCTSK
SCHEMBL606309 0.84 ACE (0.79) ACEPPARAPPARGCTSSCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851449-B2 Peptide, pharmaceutical composition, and a method of treating microcirculation disorders Obschestvo S Ogranichennoi Otvetstvennostyu “SIA Peptides” (RU) 2010-12-14 US disclosed
EP-2024387-B1 PEPTIDE SUBSTANCE ENHANCING CAPILLARIES RESISTANCE, PHARMACEUTICAL COMPOSITION ON ITS BASE AND METHOD OF ITS APPLICATION OBSCHESTVO S OGRANICHENNOI OTV (RU) 2009-10-21 EP disclosed
US-20090099098-A1 PEPTIDE SUBSTANCE ENHANCING CAPILLARIES RESISTANCE, PHARMACEUTICAL COMPOSITION ON ITS BASE AND METHOD OF ITS APPLICATION OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTYU "SIA PEPTIDES" (RU) 2009-04-16 US disclosed
EP-2024387-A1 PEPTIDE SUBSTANCE ENHANCING CAPILLARIES RESISTANCE, PHARMACEUTICAL COMPOSITION ON ITS BASE AND METHOD OF ITS APPLICATION Obschestvo S Ogranichennoi Otvetstvennostyu "sia Peptides" (RU) 2009-02-18 EP disclosed
US-7442788-B2 Antisense molecules and method of controlling expression of gene function by using the same JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) 2008-10-28 US disclosed
WO-2007136294-A1 PEPTIDE SUBSTANCE ENHANCING CAPILLARIES RESISTANCE, PHARMACEUTICAL COMPOSITION ON ITS BASE AND METHOD OF ITS APPLICATION OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTYU 'SIA PEPTIDES' (RU) 2007-11-29 WO disclosed
US-6872809-B2 Nucleoside derivatives JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) 2005-03-29 US disclosed
US-20030208050-A1 Nucleoside derivatives JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) 2003-11-06 US disclosed
US-20030162739-A1 Antisense molecules and method of controlling expression of gene function by using the same JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) 2003-08-28 US disclosed
EP-1295892-A1 ANTISENSE MOLECULES AND METHOD OF CONTROLLING EXPRESSION OF GENE FUNCTION BY USING THE SAME Japan Science and Technology Corporation (JP) 2003-03-26 EP disclosed
EP-1295891-A1 NUCLEOSIDE DERIVATIVES Japan Science and Technology Corporation (JP) 2003-03-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030162739-A1 Antisense molecules and method of controlling expression of gene function by using the same RNGTT, RNMT, UPF1 ACE 4328/4885PPARA 3638/4885PPARG 2555/4885
US-20030208050-A1 Nucleoside derivatives RIMKLA, MTHFD1, AADAT ACE 3230/4885PPARA 4053/4885PPARG 3739/4885
US-20090099098-A1 PEPTIDE SUBSTANCE ENHANCING CAPILLARIES RESISTANCE, PHARMACEUTICAL COMPOSITION ON ITS BASE AND METHOD OF ITS APPLICATION VIP, ASNS, FLT1 ACE 391/4885PPARA 3584/4885PPARG 2949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.